281.90%! Notch Therapeutics’ Third Quarter Net Profit Soars, Yet Many Pharmaceutical Companies See Significant Declines!

According to the latest statistics, as of October 23, at least 12 pharmaceutical companies have published financial reports for the third quarter of 2024. In terms of net income growth, Notch Therapeutics performed particularly well, with a staggering 281.90% increase in net income. It was followed by Gan & Lee Pharmaceuticals and 3SBio Inc., whose net income rose 57.47 percent and 42.18 percent, respectively.

Among those businesses, Notch Therapeutics released its third-quarter 2024 results announcement. The announcement showed that the company's revenue in the first three quarters of 2024 was about 1.252 billion yuan, an increase of 76.51 percent year-on-year. Net profit attributable to shareholders of the listed company was approximately RMB 350 million, an increase of 281.9% year-on-year. Basic earnings per share was 1.62 yuan, an increase of 276.74%. The significant increase in performance was mainly due to the significant increase in revenues such as peptide apis.

Gan & Lee Pharmaceuticals also reported its third quarter financial results. The report shows that the company achieved an operating income of 930 million yuan in the third quarter of 2024, an increase of 37.61% year-on-year; Net profit was 208 million yuan, up 57.47% year-on-year. The Company pointed out that in the second quarter of 2024, the company actively participated in the bidding work of the national centralized drug procurement (insulin special continuation) organized by the state, and all products were successfully selected. A new round of insulin collection began to be implemented by the provinces in the second and third quarters, and the revenue growth effect of the company's product price increase initially appeared in the third quarter.

3SBio Inc. also announced its results for the third quarter of 2024. The announcement shows that the company's revenue in the first three quarters of 2024 is about 939 million yuan, an increase of 28.58%; Net profit attributable to shareholders of the listed company was approximately 233 million yuan, an increase of 42.18%; Basic earnings per share were 0.38 yuan, an increase of 40.74%.

Mikrogen GmbH also announced its results for the third quarter of 2024. According to the announcement, the company's revenue in the first three quarters of 2024 was about 1.948 billion yuan, a decrease of 7.92% year-on-year; Net profit attributable to shareholders of listed companies was about 281 million yuan, an increase of 4.72%; Basic earnings per share was 0.4635 yuan, an increase of 5.65%.

Lai Mei Pharmaceutical also disclosed its financial report for the third quarter of 2024. The company achieved 606 million yuan in operating income in the first three quarters, down 6.07 percent year on year, the report showed. Net profit loss attributable to the parent company was 26.467 million yuan, compared to a loss of 545.138 million yuan in the same period of the previous year.

However, not all drug companies are performing well. For example, Fushilai released its financial report for the third quarter of 2024. The report shows that the company achieved a net profit attributable to shareholders of listed companies of 13,844,196.55 yuan in the first three quarters of 2024, down 87.08% year-on-year.

Yiduoli also released its financial report for the third quarter of 2024. The report shows that the company achieved an operating income of 211 million yuan in the third quarter of 2024, down 3.52% year-on-year; Net profit was 10.15 million yuan, down 79.64% year-on-year.

Yiqiao Shenzhou also disclosed its financial report for the third quarter of 2024. The company achieved 465 million yuan in operating income in the first three quarters, down 2.33 percent year on year, the report showed. The net profit attributable to the parent company was 99.3153 million yuan, down 51.6% year-on-year.

David Medical also released its third quarter 2024 results announcement. According to the announcement, the company's revenue in the first three quarters of 2024 was about 403 million yuan, a decrease of 12.21% year-on-year; The net profit attributable to shareholders of the listed company was approximately 63.31 million yuan, a decrease of 48.44% year-on-year.

Longshen Rongfa also announced its results for the third quarter of 2024. According to the announcement, the company's revenue in the first three quarters of 2024 was about 806 million yuan, a decrease of 0.75% year-on-year; Net profit attributable to shareholders of listed companies was approximately 24.77 million yuan, a decrease of 47.11%; Basic earnings per share were 0.0816 yuan, down 47.15% from the same period last year.

Zhenghai Bio also released its third quarter 2024 results announcement. According to the announcement, the company's revenue in the first three quarters of 2024 was about 291 million yuan, a decrease of 9.46% year-on-year; Net profit attributable to shareholders of the listed company was approximately 125 million yuan, a decrease of 15.69% compared with the same period last year; Basic earnings per share were 0.69 yuan, down 15.85% from the same period last year.

Finally, Shanhe Pharmaceutical Auxiliary also disclosed its financial report for the third quarter of 2024. The report shows that the company achieved an operating income of 644 million yuan in the first three quarters, up 0.62 percent year on year; Net profit attributable to the parent company was 122 million yuan, down 0.89% year-on-year; Net profit after deducting non-recurring gains and losses was 105 million yuan, down 5.12% year-on-year.